LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024..

瑞士洛桑，2024年6月27日（环球通讯社）--ADC Therapeutics SA（纽约证券交易所：ADCT）今天宣布，该公司将在2024年罗素美国指数年度重组结束时加入罗素2000®指数和广义市场罗素3000®指数，自2024年7月1日周一美国股市开放时生效。。

“We are pleased to be joining the Russell 2000® Index,” said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. “This is a significant benchmark validating the focused execution of our corporate and capital allocation strategy and our progress toward multiple upcoming expected milestones throughout our hematology and solid tumor portfolios.”.

ADC Therapeutics首席执行官Ameet Mallik表示：“我们很高兴加入Russell 2000®指数。“这是一个重要的基准，验证了我们公司和资本配置战略的重点执行，以及我们在血液学和实体瘤投资组合中朝着多个即将到来的预期里程碑取得的进展。”。

The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes.

截至4月30日（星期二），罗素美国指数（RussellUSIndex）年度重组涵盖了4000只最大的美国股票，按总市值排名。美国all cap Russell 3000®指数的会员资格有效期为一年，意味着自动纳入大盘Russell 1000®指数或小盘Russell 2000®指数以及适当的增长和价值风格指数。

FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes..

富时罗素指数主要通过目标、市值排名和风格属性来确定其罗素指数的成员资格。。

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of December 2023, about $10.5 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, a prominent global index provider..

罗素指数被投资经理和机构投资者广泛用于指数基金，并作为积极投资策略的基准。根据截至2023年12月底的数据，大约10.5万亿美元的资产以罗素美国指数为基准，罗素美国指数属于全球著名指数提供商富时罗素。。

For more information on the Russell 2000® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.

有关罗素2000®指数和罗素指数重组的更多信息，请访问富时罗素网站上的“罗素重组”部分。

About ADC Therapeutics

关于ADC治疗

ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics（纽约证券交易所：ADCT）是抗体-药物偶联物（ADC）领域的商业舞台全球领导者和先驱。该公司正在推进其专有的ADC技术，以改变血液恶性肿瘤和实体瘤患者的治疗模式。

ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy.

ADC Therapeutics的CD19定向ADC ZYNLONTA（loncastuximab tesirine lpyl）获得了FDA的加速批准，并获得了欧盟委员会的条件性批准，用于治疗两种或多种全身治疗后复发或难治性弥漫性大B细胞淋巴瘤。ZYNLONTA也正在与其他药物和早期治疗方案联合开发。

In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development..

除ZYNLONTA外，ADC Therapeutics在正在进行的临床和临床前开发中还拥有多个ADC。。

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in London and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on LinkedIn.

ADC Therapeutics总部位于瑞士洛桑（Biopôle），并在伦敦和新泽西州开展业务。有关更多信息，请访问https://adctherapeutics.com/并在LinkedIn上关注该公司。

ZYNLONTA® is a registered trademark of ADC Therapeutics SA.

ZYNLONTA®是ADC Therapeutics SA的注册商标。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “would”, “expect”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “seem”, “seek”, “future”, “continue”, or “appear” or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words.

本新闻稿包含1995年《私人证券诉讼改革法案》安全港条款所指的前瞻性声明。在某些情况下，您可以通过术语来识别前瞻性陈述，例如“可能”，“将”，“应该”，“将”，“期望”，“打算”，“计划”，“预期”，“相信”，“估计”，“预测”，“潜在”，“似乎”，“寻求”，“未来”，“继续”或“出现”或这些术语或类似表达的否定词，尽管并非所有前瞻性陈述都包含这些识别词。

Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the success of the Company’s updated corporate strategy including operating efficiencies, capital deployment and portfolio prioritization; the Company’s ability to achieve the decrease in total operating expenses for 2024, the expected cash runway into mid-2026, the effectiveness of the new commercial go-to-market strategy, competition from new technologies, and the Company’s ability to grow ZYNLONTA® revenue in the United States; Swedish Orphan Biovitrum AB (Sobi®) ability to successfully commercialize ZYNLONTA® in the European Economic Area and market acceptance, adequate reimbursement coverage, and future revenue from the same; approval by the NMPA of the BLA for ZYNLONTA® in China submitted by Overland ADCT BioPharma and future revenue from the same, our strategic partners’, including Mitsubishi Tanabe Pharma Corporation, ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions, and the timing and amount of future revenue and payments to us from such partnerships; the timing and future success .

前瞻性陈述受到某些风险和不确定性的影响，这些风险和不确定性可能导致实际结果与所描述的结果存在重大差异。可能导致这种差异的因素包括但不限于：公司更新的公司战略的成功，包括运营效率、资本部署和投资组合优先级；公司实现2024年总运营费用下降的能力、2026年年中的预期现金跑道、新商业上市战略的有效性、新技术的竞争以及公司在美国增加ZYNLONTA®收入的能力；；NMPA批准Overland ADCT BioPharma提交的ZYNLONTA®在中国的BLA，以及我们的战略合作伙伴（包括三菱田边制药公司）的未来收入，在外国司法管辖区获得ZYNLONTA®监管批准的能力，以及此类合作伙伴未来收入和付款的时间和金额；时机和未来的成功。

CONTACTS:

联系人：

Investors

投资者

Marcy Graham

Marcy Graham

ADC Therapeutics

ADC治疗学

Marcy.Graham@adctherapeutics.com

Marcy.Graham@adctherapeutics.com

+1 650-667-6450

+1 650-667-6450

Media

媒体

Nicole Riley

赖莉

ADC Therapeutics

ADC治疗学

Nicole.Riley@adctherapeutics.com

Nicole.Riley@adctherapeutics.com

+1 862-926-9040

+1 862-926-9040